ARK Investment Management LLC Has $38.12 Million Stock Position in Personalis, Inc. (NASDAQ:PSNL)

ARK Investment Management LLC raised its position in shares of Personalis, Inc. (NASDAQ:PSNL) by 11.4% in the third quarter, Holdings Channel reports. The fund owned 7,085,523 shares of the company’s stock after buying an additional 723,637 shares during the quarter. ARK Investment Management LLC owned about 0.14% of Personalis worth $38,120,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Jacobs Levy Equity Management Inc. grew its holdings in Personalis by 144.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company’s stock valued at $1,224,000 after buying an additional 485,822 shares during the last quarter. Acadian Asset Management LLC increased its position in Personalis by 90.7% during the first quarter. Acadian Asset Management LLC now owns 991,828 shares of the company’s stock worth $1,476,000 after acquiring an additional 471,646 shares during the period. Semanteon Capital Management LP acquired a new position in Personalis during the 3rd quarter valued at $375,000. Price T Rowe Associates Inc. MD boosted its holdings in Personalis by 58.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company’s stock valued at $142,000 after purchasing an additional 34,900 shares during the period. Finally, Virtu Financial LLC acquired a new stake in Personalis in the 1st quarter worth $41,000. 61.91% of the stock is currently owned by institutional investors.

Personalis Trading Down 22.6 %

Shares of PSNL opened at $4.32 on Friday. The stock has a 50 day simple moving average of $5.15 and a 200-day simple moving average of $3.32. Personalis, Inc. has a 1 year low of $0.89 and a 1 year high of $7.20. The stock has a market cap of $229.31 million, a PE ratio of -2.63 and a beta of 1.94.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.10. Personalis had a negative net margin of 101.78% and a negative return on equity of 56.87%. The firm had revenue of $22.58 million for the quarter, compared to analysts’ expectations of $19.81 million. During the same period in the prior year, the firm earned ($0.50) earnings per share. On average, sell-side analysts forecast that Personalis, Inc. will post -1.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on PSNL shares. HC Wainwright upped their price objective on shares of Personalis from $7.50 to $9.00 and gave the company a “buy” rating in a research report on Monday, August 19th. BTIG Research raised their price objective on Personalis from $5.50 to $7.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Finally, Needham & Company LLC reissued a “buy” rating and set a $7.25 price objective on shares of Personalis in a report on Thursday.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.